Filing summary
Entity and period: The supplied filing is LRAD Corporation’s Form 10-Q for the quarter ended June 30, 2012, not a filing identified as Genasys Inc. It covers the three- and nine-month periods ended June 30, 2012; the company’s fiscal year ended September 30. LRAD designs and sells directed-sound technologies and products.
Financial performance and liquidity
| Metric | Three months ended June 30, 2012 | Nine months ended June 30, 2012 |
|---|---|---|
| Revenue | $3.16 million; up 32.7% year over year | $9.17 million; down 54.3% |
| Gross profit / margin | $1.57 million / 49.8% (38.0% prior year) | $4.64 million / 50.6% (63.5% prior year) |
| Operating income | $40,078, versus an operating loss of $728,047 | $45,114, versus $4.64 million |
| Net income | $200,376, versus a net loss of $683,834 | $222,434, versus $4.67 million |
| Net income per share | $0.01, versus a loss of $0.02 | $0.01, versus $0.15 |
For the nine months, continuing-operations cash from operations was $649,470; investing used $156,504, and financing provided no cash. Cash and cash equivalents were $14.36 million at June 30, 2012, up from $13.87 million at September 30, 2011. Restricted cash was $645,656. Working capital was $19.77 million; current liabilities were $1.15 million. The company reported no debt.
Changes and management commentary
- Quarterly revenue rose mainly because of increased deliveries to the U.S. Army. Quarterly gross margin improved with favorable product mix and lower freight costs.
- Nine-month revenue and earnings fell sharply because the prior-year period included a $12.1 million shipment to a foreign military customer that did not recur. The prior-year sale also benefited from volume pricing and production absorption.
- Management expects quarterly revenue to remain uneven, citing customer budget cycles and developing markets. It described global opportunities and product-line interest, while identifying constrained military budgets, delayed U.S. government spending, and difficult international market conditions as risks.
- Management expected R&D spending for the rest of fiscal 2012 to be comparable to the prior year and stated that current cash and planned operations should fund the next 12 months. It cautioned that additional financing could be needed and might not be available on satisfactory terms.
Notable items, risks, and contingencies
- The nine-month tax benefit was $150,818, associated with amended returns and an election to carry back eligible net operating losses. Management said it expected a zero annual effective tax rate and maintained a full valuation allowance on deferred tax assets.
- Customer concentration was significant: one customer represented 39% of quarterly revenue. Three customers represented 18%, 11%, and 10% of nine-month revenue. Two customers accounted for 24% and 19% of receivables at June 30.
- Restricted cash supported bank guarantees for a customer contract. Management expected $606,250 to be released during fiscal 2012, subject to approval; $39,406 was designated noncurrent for extended warranty coverage.
- A derivative lawsuit filed July 24, 2012 alleges that options granted to certain directors and officers were issued below fair market value and contrary to the equity plan. The company and defendants said they considered the claims meritless and intended to defend the case.
- Disclosure controls were concluded effective at the reasonable-assurance level as of June 30, 2012. The filing reported no material change in internal control during the quarter.
Important facts for investors to verify
- Confirm the issuer: the provided filing names LRAD Corporation, while the request identifies Genasys Inc.
- Assess whether current revenue can be sustained without the large prior-year foreign military shipment, and monitor order timing and government-budget exposure.
- Review customer concentration, receivable collection, inventory levels, and the timing and conditions for releasing restricted cash.
- Separate recurring operating performance from the tax benefit and compare margins across periods given the unusually different sales mix.
- Monitor the option-related litigation and potential dilution from outstanding options and warrants.